[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546825":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":46,"responsibleParty":153,"collaborators":44,"id":155,"slug":156,"hasResults":157,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":44,"eligibilityCriteria":161,"healthyVolunteers":157,"sex":162,"minAge":163,"maxAge":44,"enrollmentInfo":164,"targetDuration":44,"studyType":167,"phases":168,"briefSummary":170,"conditions":171,"keywords":44,"overallStatus":49,"whyStopped":44,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":182},{"fullName":5,"class":6},"Bracco Diagnostics, Inc","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Bolus administration","ACTIVE_COMPARATOR","Bolus administration of 2 mL undiluted Lumason®",[13],"Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]",{"label":15,"type":16,"description":17,"interventionNames":18},"Continuous infusion","EXPERIMENTAL","Continuous infusion of 8 mL of diluted Lumason®",[19],"Drug: Lumason",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]","Bolus administration of 2 mL undiluted Lumason®, to be administered in 20 seconds",[9],[27],"Bolus Administration",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Lumason","Continuous infusion of 8 mL of diluted Lumason® (4 mL of Lumason® diluted in 4 mL of saline) at a rate of 1.0 mL\u002Fmin",[15],[33],"Infusion Administration",[35],{"name":36,"affiliation":37,"role":38},"Jose Banchs, MD","Sr. Medical Director","STUDY_DIRECTOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Rushil Sankpal","CONTACT","609-514-2267",null,"rushil.sankpal@diag.bracco.com",[47,69,86,105,126,137],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Interventional Cardiology Medical Group","RECRUITING","West Hills","California","91307","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-118.64398,34.19731,{"lat":59,"lon":58},[62,66],{"name":63,"role":42,"phone":64,"phoneExt":44,"email":65},"Michael Fam, MD","818-743-0666","mfam@elegantrd.com",{"name":67,"role":68,"phone":44,"phoneExt":44,"email":44},"Farhad Rafii, MD","PRINCIPAL_INVESTIGATOR",{"facility":70,"status":49,"city":71,"state":72,"zip":73,"country":53,"countryCode":54,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Piedmont Heart Institute","Atlanta","Georgia","30309",{"type":56,"coordinates":75},[76,77],-84.38798,33.749,{"lat":77,"lon":76},[80,84],{"name":81,"role":42,"phone":82,"phoneExt":44,"email":83},"Suzanne Corley","404-605-3118","suzanne.corley@piedmont.org",{"name":85,"role":68,"phone":44,"phoneExt":44,"email":44},"Venkateshwar Polsani, MD",{"facility":87,"status":49,"city":88,"state":89,"zip":90,"country":53,"countryCode":54,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Beth Israel Deaconess Medical Center","Boston","Massachusetts","02215",{"type":56,"coordinates":92},[93,94],-71.05977,42.35843,{"lat":94,"lon":93},[97,100,103],{"name":98,"role":42,"phone":44,"phoneExt":44,"email":99},"Constance Angell-James, MPH","cangellj@bidmc.harvard.edu",{"name":101,"role":42,"phone":44,"phoneExt":44,"email":102},"Madeline Cassidy","mcassid6@bidmc.harvard.edu",{"name":104,"role":68,"phone":44,"phoneExt":44,"email":44},"Jordan Strom, MD",{"facility":106,"status":107,"city":108,"state":109,"zip":110,"country":53,"countryCode":54,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Oregon Health and Sciences University","NOT_YET_RECRUITING","Portland","Oregon","97239",{"type":56,"coordinates":112},[113,114],-122.67621,45.52345,{"lat":114,"lon":113},[117,121,123],{"name":118,"role":42,"phone":119,"phoneExt":44,"email":120},"Amy Koski","503-360-6705","koskia@ohsu.edu",{"name":122,"role":68,"phone":44,"phoneExt":44,"email":44},"David German, MD",{"name":124,"role":125,"phone":44,"phoneExt":44,"email":44},"Brian Davidson, MD","SUB_INVESTIGATOR",{"facility":127,"status":128,"city":129,"state":130,"zip":131,"country":53,"countryCode":54,"cosmosGeoPoint":132,"geoPoint":136,"contacts":44},"University of Texas Medical Branch","WITHDRAWN","Galveston","Texas","77555",{"type":56,"coordinates":133},[134,135],-94.7977,29.30135,{"lat":135,"lon":134},{"facility":138,"status":49,"city":139,"state":130,"zip":140,"country":53,"countryCode":54,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Vital Heart and Vein","Humble","77338",{"type":56,"coordinates":142},[143,144],-95.26216,29.99883,{"lat":144,"lon":143},[147,151],{"name":148,"role":42,"phone":149,"phoneExt":44,"email":150},"Ovee Muhebb","281-572-0109","s.muhebb@vitalheartandvein.com",{"name":152,"role":68,"phone":44,"phoneExt":44,"email":44},"Patrick Kee, MD",{"type":154,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR","100546825","phase-3-lumason-infusion-vs-bolus-administrations-100546825",false,"NCT06400004","Lumason® Infusion vs. Bolus Administrations","A Phase III Crossover Study to Evaluate Bolus Versus Continuous Infusion of Lumason® in Patients With Suboptimal Unenhanced Echocardiography","Inclusion Criteria:\n\n* Are at least 18-years old;\n* Have suboptimal LV EBD, defined as ≥2 adjacent segments in any apical view that cannot be visualized, at pre-contrast echocardiogram;\n* Provide their written informed consent and are willing to comply with protocol requirements.\n\nExclusion Criteria:\n\n* Patient has severe congestive heart failure (class IV according to the classification of the New York Heart Association);\n* Patient has uncontrolled angina (i.e., uncontrolled on medication);\n* Patient had a recent myocardial infarction (within the last 3 days and not stabilized);\n* Patient has severe arrhythmia, that in the opinion of the Investigator, would interfere with the study conduct;\n* Patient has severe pulmonary hypertension, that in the opinion of the Investigator, would interfere with the study conduct;\n* Patient had been treated with any other contrast medium, either intravascular or orally, within 48 hours prior to the first administration;\n* Has any known allergy to one or more of the ingredients of the investigational product;\n* Is pregnant or lactating. Exclude the possibility of pregnancy by: testing on site (serum or urine βHCG) prior to the start of investigational product administration; surgical history (e.g., tubal ligation or hysterectomy); post-menopausal with a minimum 1 year without menses;\n* Has previously entered the study or have received any other investigational drug within 30 days prior to admission in this study;\n* Is determined by the Investigator that the patient is clinically unsuitable for the study.","ALL","18 Years",{"count":165,"type":166},106,"ESTIMATED","INTERVENTIONAL",[169],"PHASE3","A phase III study designed as a randomized, within-patient comparison of continuous infusion of diluted Lumason® versus the bolus administration of undiluted Lumason® for degree of LVO and assessment of LV EBD (co-primary endpoints).",[172],"Heart Diseases","2026-03-04",{"date":175,"type":176},"2026-03-05","ACTUAL",{"date":178,"type":176},"2024-07-10",{"date":180,"type":166},"2026-12-31",{"name":5,"class":6},6]